Working… Menu

Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease. (PRESTIGIO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04098315
Recruitment Status : Recruiting
First Posted : September 23, 2019
Last Update Posted : September 23, 2019
ViiV Healthcare
Information provided by (Responsible Party):
Castagna Antonella, Ospedale San Raffaele

Brief Summary:

The PRESTIGIO Registry is an Observational, prospective, multicentre study that includes patients, regularly followed by Italian Infectious Disease Centres, with HIV-1 infection and documented resistance to the 4 classes of antiretroviral drugs: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), and integrase inhibitors (INSTI).

Main objective of this register is to evaluate in the study population:

  • the long-term effectiveness of different antiretroviral regimes;
  • evolution of the genotype and phenotypic susceptibility of antiretroviral drugs used in patients with virological failure;
  • mortality;
  • incidence of opportunistic AIDS-related infections and chronic conditions (comorbidity);
  • determinants of clinical outcomes including virological/immunological/inflammatory markers.
  • antiretroviral therapy (ART) compliance and health assessments;
  • drug-economy indications related to the clinical management of this complex sub-population.

Condition or disease Intervention/treatment
HIV-1-infection Multi-Antiviral Resistance Other: REGISTER CREATION

Detailed Description:

The PRESTIGIO Register consists of a systematic and continuous collection of data on clinical, laboratory and treatment characteristics of patients with documented resistance to the 4 classes of antiretroviral drugs that meet the defined inclusion and exclusion criteria.

All the clinical centres of Infectious Diseases of the different Italian regions can participate in the implementation of the Registry. Based on an analysis conducted on data collected in an AIFA register, established for the purpose of monitoring the use of dolutegravir (DTG) 50 mg Bis in Die (BID) and containing about 200 patients with the criteria specified in this protocol, the size currently conceivable for this register in Italy is about 300 patients.

The collection of clinical information and biological samples will begin once the Ethics Committee of the participating centers has approved the participation in the registry and will continue for at least three years.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Registro Italiano Dei Pazienti Con Infezione da HIV-1 Con RESistenza Agli Inibitori Della Trascrittasi Inversa, Dell'InteGrasI e Della PrOteasi Virale (PRESTIGIO)
Actual Study Start Date : December 14, 2017
Estimated Primary Completion Date : March 31, 2020
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Intervention Details:
    Build a national registry of patients with HIV-1 infection and documented resistance to the 4 classes of antiretroviral drugs.

Primary Outcome Measures :
  1. Collection of date to evaluate: - Long-term effectiveness of different ART; -comorbidity and mortality; - ART compliance and health assessments; - drug-economy indications related to the clinical management. [ Time Frame: each 1 year ]

    to evaluate the characteristics of the study population, will be carry out specific observational studies with the following collected data:

    • demographic characteristics
    • clinical characteristics (HIV transmission mode, pre-ART viral load, CD4+ nadir, co-infection with hepatitis B and C viruses and previous treatments, previous AIDS events);
    • lifestyle factors
    • comorbidity (cancer, diabetes, cardiovascular disease, chronic kidney disease, liver disease, fractures and osteoporosis, cognitive dysfunction, COPD, sexually transmitted diseases);
    • antiretroviral and concomitant drugs;
    • adherence to antiretroviral therapy;
    • Laboratory parameters: CD4, CD8, HIV-RNA, lipids, glucose, liver and kidney parameters;
    • resistance tests for INSTI, NRTI, NNRTI, PI;
    • the historical genotypes (resistance and viral tropism)
    • any hospitalizations;
    • death.

Biospecimen Retention:   Samples Without DNA

At enrolment, plasma and cell samples of peripheral blood mononuclear cells(PBMCs) are collected for subsequent virological and immunological investigations. The samples to be collected for each patient are: 6 plasma aliquots (1.5-2.0 ml/each) and 6 PBMC aliquots (3-5 million/each).

Sample collection should be repeated at the end of each subsequent year of follow-up.

The collected biological samples are sent to the biobank of the coordinating centre and stored in a biological bank with ISO 9001:2000 quality certification (Biorep srl,

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   14 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The Italian PRESTIGIO register will include patients who are regularly monitored according to the principles of good clinical practice in the Italian Infectious Diseases Centres of all Italian regions.

Patients will be included in the registry once informed consent has been obtained (Annex 2) signed to allow for the recording and analysis of clinical/laboratory data and for the collection of biological samples, subject to the guarantee of anonymity and independence of therapeutic choices and clinical management, which will be the sole responsibility of the treating physician. The consent collected must be entered in the Register.


Inclusion Criteria:

  • subjects with HIV-1 infection;
  • age >14 years;
  • documented resistance to the 4 classes of antiretroviral drugs (NRTI, NNRTI, PI, INI), defined as resistance (at least intermediate) to at least one of the drugs in each class according to the Stanford algorithm. Resistance can be documented either at the time of inclusion in the study or previously documented throughout the patient's therapeutic history.

Exclusion Criteria:

  • none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04098315

Layout table for location contacts
Contact: Antonella Castagna 0226437934

Layout table for location information
Ospedale San Raffaele Recruiting
Milan, MI, Italy, 20127
Contact: Antonella Castagna    0226437934   
Sponsors and Collaborators
Castagna Antonella
ViiV Healthcare
Layout table for investigator information
Principal Investigator: Antonella Castagna San Raffaele
Layout table for additonal information
Responsible Party: Castagna Antonella, Sponsor and Principal Investigator, Ospedale San Raffaele Identifier: NCT04098315    
Other Study ID Numbers: PRESTIGIO
First Posted: September 23, 2019    Key Record Dates
Last Update Posted: September 23, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD will be shared in scientific conferences and meetings.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: Data will become available after 1 year from the first visit first patient (FVFP) and they will be available until patients registry will be updated.
Access Criteria: Must to be a partecipant of the registry.

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Castagna Antonella, Ospedale San Raffaele: